Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia.

Sentinel is a program sponsored by the US Food and Drug Administration to monitor the safety of medical products. We conducted a cohort assessment to evaluate the ability of the Sentinel Propensity Score Matching Tool to reproduce in an expedited fashion the known association between glyburide (vs....

Full description

Bibliographic Details
Published in:Epidemiology Vol. 28; no. 6; pp. 838 - 847
Main Authors: Meijia Zhou, Wang, Shirley V., Leonard, Charles E., Gagne, Joshua J., Fuller, Candace, Hampp, Christian, Archdeacon, Patrick, Toh, Sengwee, Iyer, Aarthi, Woodworth, Tiffany Siu, Cavagnaro, Elizabeth, Panozzo, Catherine A., Axtman, Sophia, Carnahan, Ryan M., Chrischilles, Elizabeth A., Hennessy, Sean, Zhou, Meijia
Format: research tables/charts Journal Article
Published: Lippincott Williams & Wilkins Nov2017
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=125535692&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 125535692
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10443983
        N07
      jtl: Epidemiology
      issn: 10443983
      maglogo: N
    pubinfo:
      dt: Nov2017
      vid: 28
      iid: 6
      pid: 433
      pub: Lippincott Williams & Wilkins
      place: Baltimore, Maryland
    artinfo:
      ui:
        125535692
        125535692
        NLM28682851
        125535692
        10.1097/EDE.0000000000000709
        NLM28682851
        125535692
      ppf: 838
      ppct: 9
      formats:
      tig:
        atl: Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia.
      aug:
        au:
          Meijia Zhou
          Wang, Shirley V.
          Leonard, Charles E.
          Gagne, Joshua J.
          Fuller, Candace
          Hampp, Christian
          Archdeacon, Patrick
          Toh, Sengwee
          Iyer, Aarthi
          Woodworth, Tiffany Siu
          Cavagnaro, Elizabeth
          Panozzo, Catherine A.
          Axtman, Sophia
          Carnahan, Ryan M.
          Chrischilles, Elizabeth A.
          Hennessy, Sean
          Zhou, Meijia
        affil: Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
      sug:
        subj:
          Glipizide Adverse Effects
          Hypoglycemic Agents Adverse Effects
          Glyburide Adverse Effects
          Sentinel Event
          Diabetes Mellitus, Type 2 Drug Therapy
          Hypoglycemia Chemically Induced
          Hypoglycemia Epidemiology
          Emergency Service Utilization
          Incidence
          Male
          Prospective Studies
          Adult
          Female
          Middle Age
          Cox Proportional Hazards Model
          Probability
          United States
          Hospitalization Statistics and Numerical Data
          Severity of Illness Indices
          Aged
          Funding Source
          Human
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Sentinel is a program sponsored by the US Food and Drug Administration to monitor the safety of medical products. We conducted a cohort assessment to evaluate the ability of the Sentinel Propensity Score Matching Tool to reproduce in an expedited fashion the known association between glyburide (vs. glipizide) and serious hypoglycemia. Thirteen data partners who contribute to the Sentinel Distributed Database participated in this analysis. A pretested and customizable analytic program was run at each individual site. De-identified summary results from each data partner were returned and aggregated at the Sentinel Operations Center. We identified a total of 198,550 and 379,507 new users of glyburide and glipizide, respectively. The incidence of emergency department visits and hospital admissions for serious hypoglycemia was 19 per 1000 person-years (95% confidence interval = 17.9, 19.7) for glyburide users and 22 (21.6, 22.7) for glipizide users. In cohorts matched by propensity score based on predefined variables, the hazard ratio (HR) for glyburide was 1.36 (1.24, 1.49) versus glipizide. In cohorts matched on a high-dimensional propensity score based on empirically selected variables, for which the program ran to completion in five data partners, the HR was 1.49 (1.31, 1.70). In cohorts matched on propensity scores based on both predefined and empirically selected variables via the high-dimensional propensity score algorithm (the same five data partners), the HR was 1.51 (1.32, 1.71). These findings are consistent with the literature, and demonstrate the ability of the Sentinel Propensity Score Matching Tool to reproduce this known association in an expedited fashion.See video abstract at, http://links.lww.com/EDE/B275.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N